Navigation Links
Anadys Pharmaceuticals to Present at the Lazard Healthcare Conference
Date:11/10/2010

SAN DIEGO, Nov. 10, 2010 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will present at the Lazard 7th Annual Healthcare Conference on Wednesday, November 17, 2010 at 11:30 a.m. EST (8:30 a.m. PST).  The conference is being held at the St. Regis New York.  Steve Worland, Ph.D., President and Chief Executive Officer of Anadys, will provide an overview of Anadys and its clinical development programs.

The presentation will be webcast at the time of presentation and can be accessed on the Investor Relations page of the Company's website at www.anadyspharma.com.  Listeners are encouraged to visit the website approximately five minutes prior to each presentation to download or install any necessary software.  A replay of the presentation  will be available approximately one hour after the live webcast concludes and will be available through December 1, 2010.  

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C.  The Company believes hepatitis C represents a large unmet medical need in which meaningful improvements in treatment outcomes may be attainable with the introduction of new medicines.  Anadys is preparing to initiate a Phase IIb study of ANA598, the Company's direct-acting antiviral or DAA, added to current standard of care for the treatment of hepatitis C.  The Company is also preparing to resume clinical development of ANA773, the Company's oral, small-molecule inducer of endogenous interferons that acts via the Toll like receptor 7, or TLR7, pathway in hepatitis C.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forw
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Anadys Pharmaceuticals to Report Fourth Quarter and Year End 2009 Financial Results
2. Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients
3. Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
4. Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results
5. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
6. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
7. Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
8. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
9. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
10. Anadys Pharmaceuticals to Present at the Needham Focus on Infectious Disease Conference
11. Anadys Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... in the course of a day - car, ... on the chemical industry to turn raw materials ... into valuable chemicals that are the ingredients of ... Sarina, who achieved outstanding progress in driving this ... using light instead of fossil fuels, has won ...
(Date:9/18/2014)... Silicon-valley Electronic Data Capture (EDC) provider ... the latest addition to Clinovo’s CRO Partnership Program. With ... Program, Clinovo further expands its global reach to Latin ... we are now able to build studies on our ... also rely on Clinovo to fully support the solution ...
(Date:9/18/2014)... Mexico City, MX (PRWEB) September 18, 2014 ... event in Mexico City, MX. ASEA is the manufacturer ... drink and the skin care product, RENU28. , ... Samuelson, Regional Vice President Duvan Botero, and ASEA Field ... L. Samuelson holds a PhD in Atomic/Medical Physics from ...
(Date:9/17/2014)... -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ) was ... Young LLP ("EY") that it was resigning effective September 11, ... the Company on September 15, 2014 and reported in PDL,s ... PDL has issued the following statement in response to the ... on the reason for the resignation of EY.  We were ...
Breaking Biology Technology:Using solar energy to turn raw materials into ingredients for every day life 2Digitaliza TXT Joins Clinovo’s CRO Partnership Program, Bringing Its Open Source EDC System, ClinCapture to Latin America 2Digitaliza TXT Joins Clinovo’s CRO Partnership Program, Bringing Its Open Source EDC System, ClinCapture to Latin America 3Announcing the ASEA Mexico Grand Opening Tour Beginning September 18th 2PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors 2PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors 3
... Thought leaders from around the world converge on ... Biomedical, Inc., a,medical technology company that markets the ... a Scientific Advisory Board. The,Board,s purpose is to ... of Provant, new product development, and further,application of ...
... DOYLESTOWN, Pa., May 20 Recognizing National,Hepatitis B Awareness ... Foundation,and the Association of Asian Pacific Community Health Organizations,(AAPCHO) ... the Health Needs of Women and Children," on May ... Honda (CA) and Charles Dent (PA). It,will call urgent ...
... CALGARY, May 20 /PRNewswire-FirstCall/ - Oncolytics Biotech ... that it has been granted,U.S. Patent 7,374,752 ... Disorders." The claims cover pharmaceutical compositions,which comprise ... the Company with additional patent protection for,reovirus ...
Cached Biology Technology:Regenesis Biomedical Appoints Scientific Advisory Board Composed of Life Science and Electronics Experts 2Regenesis Biomedical Appoints Scientific Advisory Board Composed of Life Science and Electronics Experts 3Hepatitis B Foundation and AAPCHO Sponsor Congressional Briefing on 'Zero Tolerance for Hepatitis B' 2Oncolytics Biotech Inc. Announces Issuance of 27th U.S. Patent 2
(Date:9/18/2014)... of camouflage: you don,t just blend in, the background ... uncommon as you might think. Kathryn Feller, from the ... larval life stages of many marine species are transparent. ... most creatures cannot make transparent. Feller explains that the ... eye unit with an opaque pigment to prevent light ...
(Date:9/17/2014)... the Arts and Humanities has received a $260,000 grant ... project, "The Boundaries of the Human in the Age ... a wide-ranging series of events aimed at exploring two ... artists and researchers who are exploring the boundaries of ... humanism, and the other involves the increasingly influential hypothesis ...
(Date:9/17/2014)... and their environmental impact recently scored a major win. ... on the bags, and Governor Jerry Brown is expected ... not yielding without a fight, according to an article ... newsmagazine of the American Chemical Society. , Alexander Tullo, ... campaign logged its first small victory in 1990 when ...
Breaking Biology News(10 mins):Transparent larvae hide opaque eyes behind reflections 2Mellon Foundation awards grant for major project in the humanities and sciences 2
... (SACRAMENTO, Calif.) A new UC Davis study has found ... those who earn higher wages, adding to growing evidence that ... "Our study clarifies a link that has been assumed but ... study and professor in the UC Davis Center for Healthcare ...
... of a collaborative grant from the Samuel Waxman Cancer ... designed to kill non-Hodgkin lymphoma tumor cells. The breakthrough ... The Foundation-funded investigators include Ari Melnick, M.D., of Weill ... of Maryland and Gilbert Priv, Ph.D., of the University ...
...   , ... PRINCETON, N.J. , May 10 ... R&D services, announced today that it has created a new Discovery & ... immunology services, Biomarker Center of Excellence, and Genomics Laboratory. Leveraging its minority ...
Cached Biology News:UC Davis study links obesity with lowest earnings 2Scientists design new drug type to kill lymphoma cells 2Covance Establishes New Discovery & Translational Services Group 2Covance Establishes New Discovery & Translational Services Group 3
... Immunoprecipitation kit allows a rapid and ... active FLAG-tagged protein. The immunoprecipitation is ... is a highly specific monoclonal antibody ... use of affinity resin allows an ...
... CromoCenSC is a chromogenic medium ... count of Salmonella (except S. thyphi) ... bacteria. ,The detection takes a maximum ... biochemical tests, no sterilization during preparation ...
...
...
Biology Products: